Literature DB >> 11792909

Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.

Stephen J Freedland1, George S Csathy, Frederick Dorey, William J Aronson.   

Abstract

PURPOSE: Biopsy Gleason score, serum prostate specific antigen (PSA) levels, and clinical stage are known to be independent predictors of adverse pathological features and biochemical failure after radical prostatectomy. We determine whether various prostate needle biopsy parameters were predictive of either adverse pathological findings or disease recurrence after radical prostatectomy.
MATERIALS AND METHODS: A single pathologist reviewed the prostate needle biopsy specimens of 190 men who underwent radical prostatectomy between 1991 and 2000. Biopsy specimens were examined for Gleason score, perineural invasion, number and percent of cores with cancer, and percent of total biopsy tissue with cancer and Gleason grade 4 or 5 cancer. Multivariate analysis was used to determine the prostate needle biopsy parameters and preoperative clinical variables, including serum PSA, clinical stage, patient age and race, that were most significant for predicting positive surgical margins, nonorgan confined disease, seminal vesicle invasion and biochemical failure after radical prostatectomy.
RESULTS: Of the prostate needle biopsy parameters examined percent of tissue with cancer was the strongest predictor of biochemical recurrence in the multivariate analysis (p <0.001). Percent of tissue with cancer was a stronger predictor of biochemical recurrence than either PSA (p = 0.048) or biopsy Gleason score (p = 0.053). It was also a strong independent predictor of seminal vesicle invasion (p = 0.015) and nonorgan confined disease (p = 0.024). Perineural invasion, percent and number of cores with cancer, and percent of tissue with Gleason grade 4 or 5 were not independent predictors of either adverse pathology or biochemical failure.
CONCLUSIONS: Of all the preoperative variables examined, including the standard clinical variables of serum PSA, Gleason score and clinical stage, percent of biopsy tissue with cancer was the strongest predictor of biochemical recurrence, seminal vesicle invasion and nonorgan confined disease. Consideration should be given to reporting percent of total biopsy tissue with cancer in all prostate biopsy results.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792909     DOI: 10.1097/00005392-200202000-00015

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  22 in total

Review 1.  Histopathology reporting of prostate needle biopsies. 2005 update.

Authors:  Rodolfo Montironi; Remigio Vela Navarrete; Antonio Lopez-Beltran; Roberta Mazzucchelli; Gregor Mikuz; Aldo V Bono
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

2.  Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy.

Authors:  Sıtkı Ün; Hakan Türk; Osman Koca; Rauf Taner Divrik; Ferruh Zorlu
Journal:  Turk J Urol       Date:  2015-06

3.  Various morphometric measurements of cancer extent on needle prostatic biopsies: which is predictive of pathologic stage and biochemical recurrence following radical prostatectomy?

Authors:  Maisa M Q Quintal; Luciana R Meirelles; Leandro L L Freitas; Luis A Magna; Ubirajara Ferreira; Athanase Billis
Journal:  Int Urol Nephrol       Date:  2011-02-22       Impact factor: 2.370

4.  Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients.

Authors:  Chinonyerem Okoro; Arvin K George; M Minhaj Siddiqui; Soroush Rais-Bahrami; Annerleim Walton-Diaz; Nabeel A Shakir; Jason T Rothwax; Dima Raskolnikov; Lambros Stamatakis; Daniel Su; Baris Turkbey; Peter L Choyke; Maria J Merino; Howard L Parnes; Bradford J Wood; Peter A Pinto
Journal:  J Endourol       Date:  2015-07-23       Impact factor: 2.942

5.  Important preoperative prognostic factors for extracapsular extension, seminal vesicle invasion and lymph node involvement in cases with radical retropubic prostatectomy.

Authors:  A Ozgür; F F Onol; L N Türkeri
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

6.  Synoptic Versus Narrative Reporting of Prostate Biopsies at a Tertiary Healthcare Institution: Challenges, successes and expectations.

Authors:  Nnamdi O Orah; Charles C Anunobi; Rufus W Ojewola
Journal:  Sultan Qaboos Univ Med J       Date:  2017-10-10

7.  The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms.

Authors:  Radka Stoyanova; Niraj H Pahlajani; Brian L Egleston; Mark K Buyyounouski; David Y T Chen; Eric M Horwitz; Alan Pollack
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

8.  Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database.

Authors:  David E Kang; Nicholas J Fitzsimons; Joseph C Presti; Christopher J Kane; Martha K Terris; William J Aronson; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

9.  Prediction of perineural invasion and its prognostic value in patients with prostate cancer.

Authors:  Jun Taik Lee; Seungsoo Lee; Chang Jin Yun; Byung Joo Jeon; Jung Man Kim; Hong Koo Ha; Wan Lee; Moon Kee Chung
Journal:  Korean J Urol       Date:  2010-11-17

Review 10.  Seminal vesicle biopsies: an useful staging procedure-exposure of seminal vesicle biopsies protocol and review of the literature.

Authors:  Raúl Montoya-Chinchilla; Antonio Rosino-Sánchez; Tomás Fernandez-Aparicio; M Carmen Cano-García; Guillermo Hidalgo-Agulló; Leandro Reina-Alcaina; Carlos Carrillo-George; Emilio Izquierdo-Morejón; Bernardino Miñana-López
Journal:  Int Urol Nephrol       Date:  2013-09-15       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.